2 news items
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
GMDAQ
27 Mar 24
, and GDA-201, an intrinsic NK (natural killer) cell therapy candidate being investigated for the treatment of hematologic malignancies. For additional
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
GMDAQ
23 Feb 24
, Gamida Cell's natural killer (NK) cell therapy candidate in ongoing Phase 1 study for non-Hodgkin lymphoma, show promising early evidence of anti-tumor
- Prev
- 1
- Next